Processa Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 18, 2026

PCSA$1.95+1.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity

Years Ended December 31, 2024 and 2025

	Additional
Common Stock · Paid-In · Treasury Stock · Accumulated
	Shares	Amount	Capital	Shares	Amount	Deficit	Total
Balance, January 1, 2024	51,640	$5	$80,658,235	(200)	$(300,000)	$(75,369,081)	$4,989,159
Stock-based compensation	2,521	1	629,513	-	-	-	629,514
Shares issued in connection with capital raises, net of transaction costs	94,253	9	7,763,070	-	-	-	7,763,079
Shares issued in connection with license agreement	200	1	188,999	-	-	-	189,000
Settlement of stock award	-	-	(8,561)	-	-	-	(8,561)
Shares withheld to pay income taxes on stock-based compensation	(306)	(1)	(15,901)	-	-	-	(15,902)
Net loss	-	-	-	-	-	(11,850,118)	(11,850,118)
Balance, December 31, 2024	148,308	15	89,215,355	(200)	(300,000)	(87,219,199)	1,696,171
Stock-based compensation	6,273	1	857,549	-	-	-	857,550
Shares issued in connection with capital raises and warrants, net of transaction costs	2,418,492	242	16,597,589	-	-	-	16,597,831
Shares withheld to pay income taxes on stock-based compensation	(959)	(1)	(10,403)	-	-	-	(10,404)
Net loss	-	-	-	-	-	(13,563,834)	(13,563,834)
Balance, December 31, 2025	2,572,114	$257	$106,660,090	(200)	$(300,000)	$(100,783,033)	$5,577,314

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.